Cost-Effectiveness of Aliskiren in Type 2 Diabetes, Hypertension, and Albuminuria

The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type...

Full description

Saved in:
Bibliographic Details
Main Authors: Delea, Thomas E., Sofrygin, Oleg, Palmer, James L., Lau, Helen, Munk, Veronica C., Sung, Jennifer, Charney, Alan, Parving, Hans-Henrik, Sullivan, Sean D.
Format: Artigo
Language:Inglês
Published: American Society of Nephrology 2009
Subjects:
Clinical Epidemiology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2754109/
https://ncbi.nlm.nih.gov/pubmed/19762496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2008111144
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items